{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:54:42Z","timestamp":1793436882016,"version":"4.5.0"},"reference-count":270,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016960","name":"Tec Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jtos.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T10:21:06Z","timestamp":1659262866000},"page":"19-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Topical glaucoma medications \u2013 Clinical implications for the ocular surface"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-8772","authenticated-orcid":false,"given":"Fredrik","family":"Fineide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Lagali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Yasin","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kolko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"Vehof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor P.","family":"Utheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2022.07.007_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II tear film report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.07.007_bib2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","article-title":"The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee","volume":"52","author":"Tomlinson","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1167\/iovs.10-6997c","article-title":"The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland","volume":"52","author":"Knop","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.07.007_bib5","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jtos.2022.07.007_bib6","article-title":"Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life","author":"Negri","year":"2019","journal-title":"J Ophthalmol. 2019"},{"key":"10.1016\/j.jtos.2022.07.007_bib7","first-page":"S20","article-title":"Current management of glaucoma and the need for complete therapy","volume":"14","author":"McKinnon","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jtos.2022.07.007_bib8","first-page":"1575","article-title":"Challenges in the clinical measurement of ocular surface disease in glaucoma patients","volume":"5","author":"Pflugfelder","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.joco.2018.07.003","article-title":"The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: a review","volume":"31","author":"Asiedu","year":"2019","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/ICU.0b013e328089f1c8","article-title":"The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review","volume":"18","author":"Yee","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/jop.2008.0140","article-title":"Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells","volume":"25","author":"Epstein","year":"2009","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib13","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1167\/iovs.08-2992","article-title":"Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage","volume":"50","author":"Pauly","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib14","first-page":"619","article-title":"Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells","volume":"40","author":"De Saint Jean","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jtos.2019.11.006","article-title":"Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease","volume":"18","author":"Zhang","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.07.007_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/eye.2012.25","article-title":"Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?","volume":"26","author":"Lockington","year":"2012","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.jtos.2022.07.007_bib17","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1097\/OPX.0000000000000542","article-title":"Ocular surface disease in glaucoma: effect of polypharmacy and preservatives","volume":"92","author":"Ramli","year":"2015","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","article-title":"Ocular surface disease and quality of life in patients with glaucoma","volume":"153","author":"Skalicky","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/112067210901900409","article-title":"Dry eye syndrome-related quality of life in glaucoma patients","volume":"19","author":"Rossi","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","article-title":"Prevalence of ocular surface disease in glaucoma patients","volume":"17","author":"Leung","year":"2008","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bjophthalmol-2012-302597","article-title":"In vivo confocal microscopy of meibomian glands in glaucoma","volume":"97","author":"Agnifili","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/IJG.0000000000000899","article-title":"Meibomian gland features and conjunctival goblet cell density in glaucomatous patients controlled with prostaglandin\/timolol fixed combinations: a case control, cross-sectional study","volume":"27","author":"Agnifili","year":"2018","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtos.2018.03.002","article-title":"Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye","volume":"16","author":"Wong","year":"2018","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.07.007_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000309394","article-title":"The influence of topical beta-blockers on the breakup time","volume":"189","author":"Strempel","year":"1984","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jtos.2022.07.007_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10792-015-0115-1","article-title":"Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment","volume":"36","author":"Romero-Diaz de Leon","year":"2016","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ajo.2004.10.021","article-title":"Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops","volume":"139","author":"Kozobolis","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/15569527.2019.1590390","article-title":"The effect of topical latanoprost on corneal clarity; 1-year prospective study(dagger)","volume":"38","author":"Sen","year":"2019","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jtos.2022.07.007_bib28","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1177\/1120672120969612","article-title":"Comparative analysis of ocular redness score evaluated automatically in glaucoma patients under different topical medications","volume":"31","author":"Giannaccare","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1471-2415-14-160","article-title":"Bimatoprost 0.01% in treatment-naive patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting","volume":"14","author":"Park","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib30","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4103\/ijo.IJO_2100_18","article-title":"Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma","volume":"67","author":"Lee","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jtos.2022.02.004","article-title":"Drug induced cicatrizing conjunctivitis: a case series with review of etiopathogenesis, diagnosis and management","volume":"24","author":"Singh","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.07.007_bib32","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1167\/iovs.10-6532","article-title":"Proteomic profiling of inflammatory signaling molecules in the tears of patients on chronic glaucoma medication","volume":"52","author":"Wong","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/bjo.82.1.39","article-title":"Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers","volume":"82","author":"Baudouin","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","article-title":"Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications","volume":"29","author":"Fechtner","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.07.007_bib35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12886-021-01917-3","article-title":"Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia","volume":"21","author":"Sahlu","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.clae.2015.02.001","article-title":"Dry eye specific quality of life in veterans using glaucoma drops","volume":"38","author":"Camp","year":"2015","journal-title":"Contact Lens Anterior Eye"},{"key":"10.1016\/j.jtos.2022.07.007_bib38","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/ICO.0b013e31823f8cb6","article-title":"Tear film osmolarity in patients treated for glaucoma or ocular hypertension","volume":"31","author":"Labbe","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.07.007_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OPTH.S9716","article-title":"Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications","volume":"4","author":"Fukuchi","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/jop.2011.0159","article-title":"Ocular surface disease and glaucoma: how to evaluate impact on quality of life","volume":"29","author":"Rossi","year":"2013","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5301\/ejo.5000220","article-title":"Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients","volume":"23","author":"Rossi","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00061198-200312000-00006","article-title":"Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects","volume":"12","author":"Stewart","year":"2003","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024129","article-title":"Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study","volume":"9","author":"Bourne","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtos.2022.07.007_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1442-9071.2003.00760.x","article-title":"Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients","volume":"32","author":"Dogan","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2008.10.019","article-title":"An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology","volume":"147","author":"Martone","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1034\/j.1600-0420.1998.760114.x","article-title":"Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility","volume":"76","author":"Kaminski","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jtos.2022.07.007_bib47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000066180","article-title":"Influence of latanoprost on the corneal epithelial barrier function in glaucoma patients","volume":"216","author":"Ishibashi","year":"2002","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jtos.2022.07.007_bib48","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00061198-200312000-00008","article-title":"Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride","volume":"12","author":"Ishibashi","year":"2003","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00184008","article-title":"Topical timolol, corneal epithelial permeability and autofluorescence in glaucoma by fluorophotometry","volume":"232","author":"Kuppens","year":"1994","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib50","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000027515","article-title":"Effect of beta-blocker eyedrops on corneal epithelial barrier function","volume":"214","author":"Niiya","year":"2000","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jtos.2022.07.007_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/0301-4738.151456","article-title":"Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues","volume":"63","author":"Kocabeyoglu","year":"2015","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0161-6420(00)00531-5","article-title":"Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study","volume":"108","author":"Lass","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.07.007_bib53","first-page":"1149","article-title":"The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes","volume":"7","author":"Tsikripis","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib54","first-page":"1158","article-title":"Effect of long-term topical latanoprost medication on conjunctival thickness in patients with glaucoma","volume":"11","author":"Li","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/jop.2018.0124","article-title":"Evaluation of antiglaucomatous drops on conjunctival thickness in patients with primary open-angle glaucoma","volume":"35","author":"Tekin","year":"2019","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib56","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1111\/aos.12131","article-title":"Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study","volume":"91","author":"Mastropasqua","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/112067210801800314","article-title":"An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes","volume":"18","author":"Ciancaglini","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib58","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/ICO.0b013e318299f161","article-title":"Scanning electron microscopy applied to impression cytology for conjunctival damage from glaucoma therapy","volume":"32","author":"Cennamo","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.07.007_bib59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajo.2006.02.056","article-title":"Effects of topical antiglaucoma application on conjunctival impression cytology specimens","volume":"142","author":"Hong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1005892426045","article-title":"The effects of long-term topical glaucoma medication on conjunctival impression cytology","volume":"21","author":"Turacli","year":"1997","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib61","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/ICO.0000000000001752","article-title":"Anterior-Segment optical coherence tomography and scanning electron microscopy to evaluate corneal epithelial changes in patients undergoing glaucoma therapy","volume":"37","author":"Cennamo","year":"2018","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.07.007_bib62","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/112067210301300608","article-title":"Impression cytology of the conjunctival epithelium after antiglaucomatous treatment with latanoprost","volume":"13","author":"Moreno","year":"2003","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib63","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0161-6420(92)31847-0","article-title":"Ocular surface alteration after long-term treatment with an antiglaucomatous drug","volume":"99","author":"Herreras","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.07.007_bib64","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1111\/aos.12261","article-title":"In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma","volume":"92","author":"Frezzotti","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib65","article-title":"Extracellular MMP-9-based assessment of ocular surface inflammation in patients with primary open-angle glaucoma","author":"Zaleska-Zmijewska","year":"2019","journal-title":"J Ophthalmol. 2019"},{"key":"10.1016\/j.jtos.2022.07.007_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201740","article-title":"Tear biomarkers in latanoprost and bimatoprost treated eyes","volume":"13","author":"Reddy","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2022.07.007_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/aos.12550","article-title":"Conjunctival matrix metalloproteinases and their inhibitors in glaucoma patients","volume":"93","author":"Helin-Toiviainen","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib68","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcjo.2014.10.006","article-title":"Prostaglandin agonist effect on matrix metalloproteinase aqueous levels in glaucoma patients","volume":"50","author":"Pradhan","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib69","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archophthalmol.2010.40","article-title":"Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface","volume":"128","author":"Honda","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib70","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41433-020-0993-y","article-title":"Evaluation of ocular surface disease in elderly patients with glaucoma: expression of matrix metalloproteinase-9 in tears","volume":"35","author":"Kim","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jtos.2022.07.007_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/02713683.2014.915574","article-title":"Increased extracellular matrix metalloproteinase inducer (EMMPRIN) expression in the conjunctival epithelium exposed to antiglaucoma treatments","volume":"40","author":"Labbe","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib72","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/eye.2015.40","article-title":"Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications","volume":"29","author":"Saini","year":"2015","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.jtos.2022.07.007_bib73","article-title":"The effect of rebamipide on ocular surface disorders induced by latanoprost and timolol in glaucoma patients","author":"Tokuda","year":"2015","journal-title":"J Ophthalmol. 2015"},{"key":"10.1016\/j.jtos.2022.07.007_bib74","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1167\/iovs.03-1067","article-title":"Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study","volume":"45","author":"Pisella","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib75","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mi.2012.43","article-title":"CX3CL1 expression in the conjunctiva is involved in immune cell trafficking during toxic ocular surface inflammation","volume":"5","author":"Denoyer","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jtos.2022.07.007_bib76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ophtha.2007.01.036","article-title":"The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways","volume":"115","author":"Baudouin","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.07.007_bib77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bjo.2006.101485","article-title":"Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs","volume":"91","author":"Malvitte","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000059624","article-title":"Ocular surface changes induced by topical antiglaucoma monotherapy","volume":"216","author":"Cvenkel","year":"2002","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jtos.2022.07.007_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/108076802317233162","article-title":"HLA-DR expression in conjunctival cells after latanoprost","volume":"18","author":"Guglielminetti","year":"2002","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib80","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/IJG.0b013e31818153f4","article-title":"Immunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatment","volume":"18","author":"Rodrigues Mde","year":"2009","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib81","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s004170100328","article-title":"Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis","volume":"239","author":"Costagliola","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib82","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3109\/02713683.2010.489181","article-title":"Influence of benzalkonium chloride on langerhans cells in corneal epithelium and development of dry eye in healthy volunteers","volume":"35","author":"Zhivov","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archopht.1996.01100130258004","article-title":"Reversal of topical antiglaucoma medication effects on the conjunctiva","volume":"114","author":"Broadway","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib84","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bjo.2008.140186","article-title":"Effect of latanoprost and timolol on the histopathology of the human conjunctiva","volume":"93","author":"Terai","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib85","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jtos.2020.06.004","article-title":"Change of tear lipid mediators in a post-trabeculectomy cohort","volume":"18","author":"Ambaw","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.07.007_bib86","article-title":"Effect of topical prostaglandin F2alpha analogs on selected oxidative stress parameters in the tear film","volume":"55","author":"Sedlak","year":"2019","journal-title":"Medicina (Kaunas)."},{"key":"10.1016\/j.jtos.2022.07.007_bib87","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/15569527.2020.1787435","article-title":"Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film","volume":"39","author":"Sedlak","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jtos.2022.07.007_bib88","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12886-021-02079-y","article-title":"Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film","volume":"21","author":"Sedlak","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib89","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10384-019-00673-8","article-title":"Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series","volume":"63","author":"Joh","year":"2019","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3341\/kjo.2019.0094","article-title":"Comparison of two combinations of maximum medical therapy for lowering intraocular pressure in primary open-angle glaucoma","volume":"34","author":"Wy","year":"2020","journal-title":"Kor J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050180","article-title":"A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits","volume":"7","author":"Brignole-Baudouin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2022.07.007_bib92","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1007\/s00216-013-6811-7","article-title":"Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry","volume":"405","author":"Desbenoit","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.jtos.2022.07.007_bib93","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","article-title":"Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies","volume":"106","author":"Baudouin","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.07.007_bib94","first-page":"57","article-title":"The effects of antiglaucomatous agents on conjunctiva used for various durations","volume":"20","author":"Ariturk","year":"1996","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib95","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1600-0420.1995.tb00276.x","article-title":"The morphology of conjunctiva after long-term topical anti-glaucoma treatment. A quantitative analysis","volume":"73","author":"Baun","year":"1995","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jtos.2022.07.007_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02850114","article-title":"Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension","volume":"20","author":"Abelson","year":"2003","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib97","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000126078","article-title":"Comparison of ocular surface side effects of topical travoprost and bimatoprost","volume":"222","author":"Alagoz","year":"2008","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jtos.2022.07.007_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097921","article-title":"Comparison of diagnostic tests in distinct well-defined conditions related to dry eye disease","volume":"9","author":"Alves","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2022.07.007_bib99","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1442-9071.2000.00237.x","article-title":"Adverse effects of topical antiglaucoma drugs on the ocular surface","volume":"28","author":"Arici","year":"2000","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/nmj.NMJ_116_19","article-title":"Effect of long-term topical antiglaucoma medication use on the ocular surface","volume":"61","author":"Awe","year":"2020","journal-title":"Niger Med J"},{"key":"10.1016\/j.jtos.2022.07.007_bib101","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1590\/S0004-27492008000100004","article-title":"Tear film and ocular surface alterations in chronic users of antiglaucoma medications","volume":"71","author":"Baffa Ldo","year":"2008","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib102","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/08820538.2017.1395891","article-title":"Ocular redness measured with the keratograph 5M in patients using anti-glaucoma eye drops","volume":"33","author":"Perez Bartolome","year":"2018","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib103","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/IJG.0000000000000316","article-title":"Vitamin A palmitate and carbomer gel protects the conjunctiva of patients with long-term prostaglandin analogs application","volume":"25","author":"Cui","year":"2016","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib104","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/OPTH.S81247","article-title":"Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma","volume":"9","author":"Cvenkel","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib105","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1089\/jop.2016.0117","article-title":"Use of topical cannabinomimetic palmitoylethanolamide in ocular surface disease associated with antiglaucoma medications","volume":"33","author":"Di Zazzo","year":"2017","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib106","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1177\/1120672120901698","article-title":"Effects of topical antiglaucomatous medications on central corneal epithelial thickness by anterior segment optical coherence tomography","volume":"30","author":"Dogan","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib107","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/eye.2013.304","article-title":"Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients","volume":"28","author":"Figus","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jtos.2022.07.007_bib108","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1442-9071.2012.02781.x","article-title":"Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication","volume":"40","author":"Ghosh","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15569527.2021.1902341","article-title":"Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study","volume":"40","author":"Guclu","year":"2021","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jtos.2022.07.007_bib110","first-page":"291","article-title":"Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients","volume":"3","author":"Horsley","year":"2009","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib111","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/0300-1652.182071","article-title":"Effect of preserved and preservative-free timolol eye drops on tear film stability in healthy Africans","volume":"57","author":"Ilechie","year":"2016","journal-title":"Niger Med J"},{"key":"10.1016\/j.jtos.2022.07.007_bib112","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00061198-200312000-00007","article-title":"Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy","volume":"12","author":"Inoue","year":"2003","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0021-5155(03)00004-2","article-title":"Ocular factors relevant to keratoepitheliopathy in glaucoma patients with and without diabetes mellitus","volume":"47","author":"Inoue","year":"2003","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib114","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/IJG.0000000000001091","article-title":"Short-term efficacy and safety of a latanoprost\/carteolol fixed combination switched from concomitant therapy to in patients with primary open-angle glaucoma or ocular hypertension","volume":"27","author":"Inoue","year":"2018","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib115","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2147\/OPTH.S240425","article-title":"Short-term efficacy and safety of switching from a latanoprost\/timolol fixed combination to a latanoprost\/carteolol fixed combination","volume":"14","author":"Inoue","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib116","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10384-016-0430-8","article-title":"Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome","volume":"60","author":"Jin","year":"2016","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib117","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/IJG.0b013e3182741f32","article-title":"Conjunctivochalasis as a contributing factor for the development of ocular surface disease in medically treated glaucoma patients","volume":"23","author":"Kocabeyoglu","year":"2014","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib118","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12325-014-0125-9","article-title":"24-hour efficacy of travoprost\/timolol BAK-free versus latanoprost\/timolol fixed combinations in patients insufficiently controlled with latanoprost","volume":"31","author":"Konstas","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib119","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/jop.2013.0132","article-title":"Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions","volume":"30","author":"Kumagami","year":"2014","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jfo.2021.03.008","article-title":"Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops","volume":"44","author":"Lajmi","year":"2021","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib121","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/eye.2013.144","article-title":"Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity","volume":"27","author":"Lee","year":"2013","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.jtos.2022.07.007_bib122","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1097\/OPX.0000000000000943","article-title":"Tear lipid layer thickness change and topical anti-glaucoma medication use","volume":"93","author":"Lee","year":"2016","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib123","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.4103\/0366-6999.164927","article-title":"Therapeutic effects of sodium hyaluronate on ocular surface damage induced by benzalkonium chloride preserved anti-glaucoma medications","volume":"128","author":"Liu","year":"2015","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.jtos.2022.07.007_bib124","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12253-014-9755-0","article-title":"Confocal microscopy of epithelial and langerhans cells of the cornea in patients using travoprost drops containing two different preservatives","volume":"20","author":"Marsovszky","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib125","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1007\/s10792-021-01947-2","article-title":"Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension","volume":"41","author":"Muz","year":"2021","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib126","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12325-016-0297-6","article-title":"Sustainability of intraocular pressure reduction of travoprost ophthalmic solution in subjects with normal tension glaucoma","volume":"33","author":"Naito","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib127","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/OPTH.S29912","article-title":"Comparison of the latanoprost 0.005%\/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%\/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial","volume":"6","author":"Nakakura","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib128","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1517\/14656566.2012.705830","article-title":"Fixed topical combinations in glaucomatous patients and ocular discomfort","volume":"13","author":"Nebbioso","year":"2012","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jtos.2022.07.007_bib129","first-page":"1117","article-title":"Treatment of glaucomatous patients by means of food supplement to reduce the ocular discomfort: a double blind randomized trial","volume":"17","author":"Nebbioso","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"Suppl 2","key":"10.1016\/j.jtos.2022.07.007_bib130","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/ICL.0000000000000405","article-title":"The effects of latanoprost with benzalkonium chloride versus travoprost with SofZia on the ocular surface","volume":"44","author":"Rahmatnejad","year":"2018","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2022.07.007_bib131","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12325-018-0699-8","volume":"35","author":"Roberti","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib132","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1517\/14656560903061283","article-title":"Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%\/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study","volume":"10","author":"Rossi","year":"2009","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jtos.2022.07.007_bib133","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/jop.2017.0104","article-title":"High prevalence of ocular surface disease among glaucoma patients in Thailand","volume":"34","author":"Ruangvaravate","year":"2018","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib134","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.6061\/clinics\/2013(10)05","article-title":"Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial","volume":"68","author":"Russ","year":"2013","journal-title":"Clinics"},{"key":"10.1016\/j.jtos.2022.07.007_bib135","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jcjo.2014.11.006","article-title":"Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study","volume":"50","author":"Saade","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib136","first-page":"931","article-title":"Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy","volume":"10","author":"Saini","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib137","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1136\/bjo.84.11.1250","article-title":"Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone","volume":"84","author":"Shimazaki","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib138","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00417-020-05067-y","article-title":"Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study","volume":"259","author":"Su","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib139","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s12325-018-0718-9","article-title":"Tafluprost\/timolol versus latanoprost\/timolol study G. Multicenter, randomized, controlled study comparing tafluprost\/timolol fixed combination with latanoprost\/timolol fixed combination in primary open-angle glaucoma and ocular hypertension","volume":"35","author":"Suzuki","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0420.2000.078001037.x","article-title":"Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension","volume":"78","author":"Thygesen","year":"2000","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jtos.2022.07.007_bib141","article-title":"Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma","author":"Tomic","year":"2013","journal-title":"Biomed Res Int. 2013"},{"key":"10.1016\/j.jtos.2022.07.007_bib142","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1089\/jop.2014.0131","article-title":"The utility of an artificial substitute to improve corneal sensitivity in glaucomatous patients on chronic therapy with prostaglandin analogs","volume":"31","author":"Vagge","year":"2015","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib143","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jop.2010.0133","article-title":"Symptoms and signs of tear film dysfunction in glaucomatous patients","volume":"27","author":"Valente","year":"2011","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib144","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/jop.2009.0134","article-title":"Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension","volume":"26","author":"Whitson","year":"2010","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib145","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0420.1995.tb00277.x","article-title":"Effects of antiglaucoma drugs on ocular surface","volume":"73","author":"Yalvac","year":"1995","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jtos.2022.07.007_bib146","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10792-019-01211-8","article-title":"Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs","volume":"40","author":"Yoon","year":"2020","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib147","article-title":"Effects of long-term antiglaucoma eye drops on conjunctival structures: an in vivo confocal microscopy study","author":"Zhu","year":"2015","journal-title":"J Ophthalmol. 2015"},{"key":"10.1016\/j.jtos.2022.07.007_bib148","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/IJG.0000000000001713","article-title":"Assessment of ocular surface disease in glaucoma patients in Ghana","volume":"30","author":"Kobia-Acquah","year":"2021","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib149","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1089\/jop.2014.0174","article-title":"Effects of switching from timolol to brimonidine in prostaglandin analog and timolol combination therapy","volume":"31","author":"Aihara","year":"2015","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib150","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0377-1237(07)80011-6","article-title":"Ocular surface changes in primary open angle glaucoma with long term topical anti glaucoma medication","volume":"63","author":"Kamath","year":"2007","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.jtos.2022.07.007_bib151","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12325-014-0109-9","article-title":"Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety","volume":"31","author":"Kuwayama","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib152","first-page":"10","article-title":"The efficacy, safety and satisfaction associated with switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of brinzolamide 1% and brimonidine 0.1% in glaucoma patients","author":"Onoe","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtos.2022.07.007_bib153","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1755-3768.1994.tb02804.x","article-title":"Efficacy and safety of timolol\/pilocarpine combination drops in glaucoma patients","volume":"72","author":"Uusitalo","year":"1994","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib154","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/ceo.13329","article-title":"Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride","volume":"46","author":"Wong","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-1-4615-2417-5_67","article-title":"Influence of various pharmaceutical agents on tear flow as assessed by fluorophotometry","volume":"350","author":"Gobbels","year":"1994","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jtos.2022.07.007_bib156","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ophtha.2004.06.023","article-title":"Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term","volume":"111","author":"Baudouin","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.07.007_bib157","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/1120672118795399","article-title":"Cytokine expression in tears of patients with glaucoma or dry eye disease: a prospective, observational cohort study","volume":"29","author":"Benitez-Del-Castillo","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib158","article-title":"Comparison of efficacy and ocular surface disease Index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients","author":"El Hajj Moussa","year":"2018","journal-title":"J Ophthalmol. 2018"},{"key":"10.1016\/j.jtos.2022.07.007_bib159","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bjo.79.4.339","article-title":"Effect of timolol with and without preservative on the basal tear turnover in glaucoma","volume":"79","author":"Kuppens","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib160","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00417-016-3299-9","article-title":"Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial","volume":"254","author":"Stalmans","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib161","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/OPTH.S14113","article-title":"Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost","volume":"4","author":"Katz","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib162","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","article-title":"Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma","volume":"97","author":"Rouland","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib163","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/IJG.0000000000001248","article-title":"Noninferiority of preservative-free versus BAK-preserved latanoprost-timolol fixed combination eye drops in patients with open-angle glaucoma or ocular hypertension","volume":"28","author":"Aptel","year":"2019","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib164","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12325-011-0038-9","article-title":"Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension","volume":"28","author":"Erb","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib165","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jfo.2018.04.012","article-title":"Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naive patients and patients intolerant to other hypotensive medications","volume":"41","author":"Lazreg","year":"2018","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020201","article-title":"Efficacy, safety and patient-reported outcomes with preservative-free (PF) tafluprost or PF-Dorzolamide\/Timolol compared with preserved latanoprost: a prospective multicenter study in Korean glaucoma patients with ocular surface disease","volume":"15","author":"Park","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jtos.2022.07.007_bib167","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2016.1202818","article-title":"Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension","volume":"32","author":"Aptel","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtos.2022.07.007_bib168","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/bjophthalmol-2013-304064","article-title":"Bimatoprost 0.03%\/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%\/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial","volume":"98","author":"Goldberg","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib169","first-page":"52","article-title":"Ocular surface evaluation after the substitution of benzalkonium chloride preserved prostaglandin eye drops by a preservative-free prostaglandin analogue","volume":"8","author":"Lopes","year":"2019","journal-title":"Med Hypothesis, Discov Innovation (MEHDI) Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/1120672118805877","article-title":"Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues","volume":"29","author":"El Ameen","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib171","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/bjophthalmol-2011-301015","article-title":"Spanish multicenter tafluprost tolerability study","volume":"96","author":"Milla","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib172","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1120672118785280","article-title":"The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension","volume":"29","author":"Misiuk-Hojlo","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib173","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10792-017-0792-z","article-title":"Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients","volume":"39","author":"Kestelyn","year":"2019","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib174","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1089\/jop.2013.0216","article-title":"Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers","volume":"30","author":"Iester","year":"2014","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","article-title":"Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib176","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib177","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/OPTH.S176605","article-title":"Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study","volume":"12","author":"Economou","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib178","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ceo.12431","article-title":"Australian, New Zealand Glaucoma Interest G. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease","volume":"43","author":"Goldberg","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib179","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s12325-020-01239-8","article-title":"Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: the VISIONARY study","volume":"37","author":"Oddone","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/IJG.0b013e3181fc8129","article-title":"Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost","volume":"21","author":"Aihara","year":"2012","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib181","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0420.1997.tb00480.x","article-title":"Chronic topical eye preservative-free beta-blocker therapy effect on the ocular surface in glaucomatous patients","author":"Campagna","year":"1997","journal-title":"Acta Ophthalmol Scand Suppl"},{"key":"10.1016\/j.jtos.2022.07.007_bib182","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jfo.2012.04.015","article-title":"Safety and efficacy of unpreserved timolol 0.1% gel in patients controlled by preserved latanoprost with signs of ocular intolerance","volume":"36","author":"Delval","year":"2013","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib183","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/15569527.2019.1680685","article-title":"Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages","volume":"39","author":"Duru","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jtos.2022.07.007_bib184","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12325-015-0205-5","article-title":"A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients","volume":"32","author":"Fogagnolo","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib185","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.4103\/ijo.IJO_165_21","article-title":"Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma","volume":"69","author":"Hagras","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib186","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1120672117753703","article-title":"Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness","volume":"28","author":"Hommer","year":"2018","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib187","article-title":"Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtos.2022.07.007_bib188","article-title":"The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study","author":"Aydin Kurna","year":"2014","journal-title":"J Ophthalmol. 2014"},{"key":"10.1016\/j.jtos.2022.07.007_bib189","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12325-016-0448-9","volume":"34","author":"Konstas","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12886-017-0453-z","article-title":"Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib191","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2004.08.028","article-title":"Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers","volume":"139","author":"Manni","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib192","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jtos.2017.03.004","article-title":"Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost","volume":"15","author":"Martinez-de-la-Casa","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.07.007_bib193","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/bjophthalmol-2019-314234","article-title":"Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives","volume":"105","author":"Murugesan","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib194","doi-asserted-by":"crossref","first-page":"694","DOI":"10.5301\/ejo.5000977","article-title":"Ocular surface disease in patients under topical treatment for glaucoma","volume":"27","author":"Perez-Bartolome","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5301\/ejo.5000006","article-title":"Timogel(R) vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance","volume":"22","author":"Rolle","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib196","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12886-017-0534-z","article-title":"Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study","volume":"17","author":"Rolle","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib197","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.2147\/OPTH.S264984","article-title":"Ocular surface changes after switching from other prostaglandins to tafluprost and preservative-free tafluprost in glaucoma patients","volume":"14","author":"Ruangvaravate","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib198","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s10384-021-00856-2","article-title":"Comparison of the 24-h efficacy and safety of fixed combination carteolol\/latanoprost and timolol\/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study","volume":"65","author":"Saito","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib199","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1167\/iovs.15-17455","article-title":"The ocular surface in medically controlled glaucoma: an in vivo confocal study","volume":"57","author":"Villani","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib200","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1089\/jop.2021.0071","article-title":"Ocular surface disease in glaucoma patients randomized to benzalkonium chloride-containing latanoprost and preservative-free bimatoprost","volume":"37","author":"Wu","year":"2021","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib201","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3341\/kjo.2021.0010","article-title":"Efficacy and safety of preservative-free latanoprost eyedrops compared with preserved prostaglandin analogues in patients with open-angle glaucoma","volume":"35","author":"Seong","year":"2021","journal-title":"Kor J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib202","first-page":"56","article-title":"Preliminary outcomes of temporary collagen punctal plugs for patients with dry eye and glaucoma","volume":"9","author":"Chen","year":"2020","journal-title":"Med Hypothesis, Discov Innovation (MEHDI) Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib203","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/IJG.0000000000001041","article-title":"Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases","volume":"27","author":"Dubrulle","year":"2018","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib204","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/OPTH.S229815","article-title":"Impact of ocular surface disease treatment in patients with glaucoma","volume":"14","author":"Mylla Boso","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib205","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IJG.0b013e318264cd68","article-title":"Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control","volume":"23","author":"Batra","year":"2014","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib206","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/ceo.13311","article-title":"Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial","volume":"46","author":"Sherwin","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib207","first-page":"40","article-title":"In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis)","volume":"110","author":"Baudouin","year":"2012","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jtos.2022.07.007_bib208","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0161-6420(92)31879-2","article-title":"Corneal epithelial permeability of dry eyes before and after treatment with artificial tears","volume":"99","author":"Gobbels","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.07.007_bib209","doi-asserted-by":"crossref","DOI":"10.1177\/1120672121991395","article-title":"The effects of ocular surface disease on optical coherence tomography test results in patients with glaucoma","author":"Oktay","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib210","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jcjo.2012.11.001","article-title":"Effect of artificial tears on automated visual field testing in patients with glaucoma and dry eye","volume":"48","author":"Kocabeyoglu","year":"2013","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib211","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000357100","article-title":"Confocal Microscopy Study G. Changes in the morphological and functional patterns of the ocular surface in patients treated with prostaglandin analogues after the use of TSP 0.5%(R) preservative-free eyedrops: a prospective, multicenter study","volume":"51","author":"Iester","year":"2014","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib212","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00061198-200204000-00007","article-title":"Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension","volume":"11","author":"Katz","year":"2002","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib213","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/108076803762718097","article-title":"A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension","volume":"19","author":"Mundorf","year":"2003","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib214","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12325-011-0003-7","article-title":"Polyquad-preserved travoprost\/timolol, benzalkonium chloride (BAK)-preserved travoprost\/timolol, and latanoprost\/timolol in fixed combinations: a rabbit ocular surface study","volume":"28","author":"Liang","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib215","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","article-title":"Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells","volume":"27","author":"Ammar","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib216","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000335984","article-title":"Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions","volume":"48","author":"Liang","year":"2012","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib217","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/02713683.2011.578781","article-title":"Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells","volume":"36","author":"Brignole-Baudouin","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib218","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/jop.2006.22.267","article-title":"Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study","volume":"22","author":"Labbe","year":"2006","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib219","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3341\/kjo.2013.27.6.446","article-title":"In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells","volume":"27","author":"Kim","year":"2013","journal-title":"Kor J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib220","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3341\/kjo.2015.29.4.270","article-title":"In vivo effects of preservative-free and preserved prostaglandin analogs: mouse ocular surface study","volume":"29","author":"Kim","year":"2015","journal-title":"Kor J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib221","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1089\/jop.2013.0248","article-title":"Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study","volume":"30","author":"Sezgin Akcay","year":"2014","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib222","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/ceo.13814","article-title":"Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: a 2-year randomized evaluation study","volume":"48","author":"Mohammed","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib223","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2147\/OPTH.S112711","article-title":"Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost","volume":"10","author":"Garcia-Feijoo","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib224","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12886-015-0151-7","article-title":"Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study","volume":"15","author":"Lopes","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib225","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14740338.2015.1017467","article-title":"From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability","volume":"14","author":"Rossi","year":"2015","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.jtos.2022.07.007_bib226","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5301\/ejo.5000001","article-title":"Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma","volume":"22","author":"Gandolfi","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib227","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/eye.2011.134","article-title":"Travoprost 0.004%\/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy","volume":"25","author":"Kitazawa","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jtos.2022.07.007_bib228","unstructured":"Mlcakova E, Mlcak P, Karhanova M, Langova K, Maresova K. [Ocular surface evaluation in patients treated with prostaglandin analogues considering preservative agent]. Ceska a Slov Oftalmol.72:120-127."},{"key":"10.1016\/j.jtos.2022.07.007_bib229","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2015.04.041","article-title":"Polyquaternium-1-Preserved travoprost 0.003% or benzalkonium chloride-preserved travoprost 0.004% for glaucoma and ocular hypertension","volume":"160","author":"Peace","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib230","first-page":"24","article-title":"The effect of long-term usage of single-agent antiglaucomatous drops with different preservatives on cornea biomechanics","volume":"6","author":"Aydemir","year":"2021","journal-title":"Beyoglu Eye J"},{"key":"10.1016\/j.jtos.2022.07.007_bib231","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1136\/bjophthalmol-2011-300012","article-title":"Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines","volume":"95","author":"Ammar","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib232","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2010.0003","article-title":"In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells","volume":"26","author":"Kahook","year":"2010","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib233","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","article-title":"Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears","volume":"27","author":"Kahook","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.07.007_bib234","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1167\/iovs.12-9685","article-title":"Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets","volume":"53","author":"Nakagawa","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib235","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1097\/IJG.0000000000000265","article-title":"Effect of switching to travoprost preserved with SofZia in glaucoma patients with chronic superficial punctate keratitis while receiving BAK-preserved latanoprost","volume":"25","author":"Aihara","year":"2016","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib236","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/j.1755-3768.2012.02565.x","article-title":"Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study","volume":"91","author":"Aihara","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib237","first-page":"71","article-title":"Efficacy and safety of topical travoprost with sofzia preservative for Japanese glaucoma patients","volume":"59","author":"Kanamoto","year":"2010","journal-title":"Hiroshima J Med Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib238","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10384-009-0754-8","article-title":"Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost","volume":"54","author":"Yamazaki","year":"2010","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib239","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s12325-013-0014-7","article-title":"Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension","volume":"30","author":"Crichton","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib240","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/jop.2014.0104","article-title":"Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface","volume":"31","author":"Kanamoto","year":"2015","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2022.07.007_bib241","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2022.07.007_bib242","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00184009","article-title":"Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma","volume":"232","author":"de Jong","year":"1994","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib243","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-9394(14)76730-3","article-title":"Conjunctival impression cytology in patients with glaucoma using long-term topical medication","volume":"112","author":"Brandt","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib244","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0161-6420(94)31322-4","article-title":"Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma","volume":"101","author":"Baudouin","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.07.007_bib245","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/archopht.1994.01090230051020","article-title":"Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib246","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0161-6420(89)32888-0","article-title":"Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients","volume":"96","author":"Sherwood","year":"1989","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.07.007_bib247","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1167\/iovs.12-9907","article-title":"Surface chemistry study of the interactions of pharmaceutical ingredients with human meibum films","volume":"53","author":"Georgiev","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib248","first-page":"415","article-title":"Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin","volume":"12","author":"Chung","year":"2006","journal-title":"Mol Vis"},{"key":"10.1016\/j.jtos.2022.07.007_bib249","first-page":"851","article-title":"Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro","volume":"18","author":"Clouzeau","year":"2012","journal-title":"Mol Vis"},{"key":"10.1016\/j.jtos.2022.07.007_bib250","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1167\/iovs.11-8775","article-title":"Corneal neurotoxicity due to topical benzalkonium chloride","volume":"53","author":"Sarkar","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib251","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s12325-009-0076-8","article-title":"The effects of combination glaucoma medications on ocular surface epithelial cells","volume":"26","author":"Ammar","year":"2009","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib252","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1167\/iovs.10-6338","article-title":"Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers","volume":"52","author":"Andres-Guerrero","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib253","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1167\/iovs.07-0266","article-title":"In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost","volume":"48","author":"Baudouin","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib254","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1076\/ceyr.27.4.253.16603","article-title":"In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system","volume":"27","author":"Blondin","year":"2003","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib255","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/02713680801971857","article-title":"In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line","volume":"33","author":"Brasnu","year":"2008","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib256","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00183432","article-title":"The effect of topical cholinergic medications on human Tenon's capsule fibroblasts in tissue culture","volume":"233","author":"Cunlife","year":"1995","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib257","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1167\/iovs.16-20903","article-title":"The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells","volume":"58","author":"Datta","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2022.07.007_bib258","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/02713683.2013.859275","article-title":"Cytoprotective effect of lacritin on human corneal epithelial cells exposed to benzalkonium chloride in vitro","volume":"39","author":"Feng","year":"2014","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2022.07.007_bib259","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129419","article-title":"Effects of four formulations of prostaglandin analogs on eye surface cells. A comparative study","volume":"10","author":"Perez-Roca","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2022.07.007_bib260","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/bjo.2008.138768","article-title":"Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride","volume":"92","author":"Liang","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.07.007_bib261","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12325-008-0078-y","article-title":"Quantitative analysis of conjunctival goblet cells after chronic application of topical drops","volume":"25","author":"Kahook","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2022.07.007_bib262","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/15569527.2014.944650","article-title":"Comparison of the ocular surface changes following the use of two different prostaglandin F2alpha analogues containing benzalkonium chloride or polyquad in rabbit eyes","volume":"34","author":"Lee","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jtos.2022.07.007_bib263","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/mi.2012.44","article-title":"Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine model","volume":"6","author":"Galletti","year":"2013","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jtos.2022.07.007_bib264","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5603\/FM.a2020.0146","article-title":"Effect of preservative-free and preserved prostaglandin analogues on the histology of cornea of adult male Guinea pigs following repeated exposure","volume":"81","author":"Ali","year":"2022","journal-title":"Folia Morphol (Warsz)."},{"key":"10.1016\/j.jtos.2022.07.007_bib265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/09273948.2012.723106","article-title":"Toxic-inflammatory effects of prostoglandin analogs on the ocular surface","volume":"21","author":"Demirel","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jtos.2022.07.007_bib266","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/IJG.0000000000000279","article-title":"The impact of glaucoma medications on corneal wound healing","volume":"25","author":"Pinheiro","year":"2016","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2022.07.007_bib267","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1017\/S1431927614000324","article-title":"In vivo laser scanning confocal microscopy of the ocular surface in glaucoma","volume":"20","author":"Mastropasqua","year":"2014","journal-title":"Microsc Microanal"},{"key":"10.1016\/j.jtos.2022.07.007_bib268","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.2174\/0929867325666181009153212","article-title":"Structural and molecular tear film changes in glaucoma","volume":"26","author":"Mastropasqua","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jtos.2022.07.007_bib269","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/ICL.0000000000000544","article-title":"Ocular surface disease and glaucoma medications: a clinical approach","volume":"45","author":"Zhang","year":"2019","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2022.07.007_bib270","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154201242200060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154201242200060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:46:05Z","timestamp":1761540365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154201242200060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":270,"alternative-id":["S154201242200060X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2022.07.007","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical glaucoma medications \u2013 Clinical implications for the ocular surface","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}